Work detail

Is women’s vaccination against HPV in the Czech Republic cost-effective?

Author: Bc. Martina Lušková
Year: 2021 - summer
Leaders: Mgr. Lenka Šlegerová
Consultants:
Work type: Bachelors
Language: English
Pages: 54
Awards and prizes:
Link:
Abstract: This thesis approaches the cost-effectiveness of women’s vaccination against human
papillomaviruses (HPV) in the Czech Republic. HPV is a pathogen responsible for the majority
of diagnosed cervical carcinomas. The aim is to assess the current reimbursement setting of
HPV vaccination compared to the designed change. In order to increase the vaccination
coverage and subsequently decrease the future treatment costs, two strategies were proposed.
A homogenous multistate Markov model is developed to model the transition among states
representing the stages of progression of the cervical carcinoma. Transition analysis is
performed based on the data collected for the purpose of healthcare reimbursement under public
health insurance. The incremental cost-effectiveness ratio suggests that increased immunization
coverage (from 65.8% to 80%) fuelled by the campaign promoting vaccination seems to be
cost-effective assuming the threshold of 1.2 million CZK per one quality-adjusted life year. The
strategy promoting the vaccination together with extending the age (from thirteen-year-olds by
cohorts of fourteen- and fifteen-year-olds) at which vaccination is reimbursed delivers
analogous outcome. The main setback of the thesis is that the data for the purpose of
reimbursement and not data from the clinical register were used. Thus, the epidemiological
situation in the Czech Republic was not reflected precisely. Despite the limitations, the
increased immunization coverage of women’s vaccination against HPV appears to be costeffective and therefore, the corresponding policy change should be implemented
December 2021
MonTueWedThuFriSatSun
  12345
6789101112
13141516171819
20212223242526
2728293031  

Partners

Deloitte

Sponsors

CRIF
McKinsey
Patria Finance